Research
Hormonal
Liraglutide 1.8 mg/day improves glycemic control (HbA1c reduction) in patients with Type 2 Diabetes compared to placebo, rosiglitazone, glimepiride, insulin glargine, and exenatide.
For Type 2 Diabetes, a daily 1.8 mg injection of liraglutide effectively lowers blood sugar, often better than insulin or other common diabetes medications, while avoiding the weight gain often caused by insulin. It is typically added to existing medications like metformin.
GoodSupportsHIGH confidence
When added to glimepiride, liraglutide (1.2 or 1.8 mg/day) had a greater reduction in glycated hemoglobin (HbA1c) when compared to placebo (p ≤ 0.0001) or to rosiglitazone (p ≤ 0.0001).
Why this rating
Based on multiple Phase III randomized clinical trials (LEAD program).
Source
A 2021 Update on the Use of Liraglutide in the Modern Treatment of ‘Diabesity’: A Narrative Review
Mariana Cornelia Tilinca et al. · Medicina · 2021
DOI 10.3390/medicina57070669
narrative_reviewCited 42×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- Liraglutide 1.8 mg/day reduces the risk of major adverse cardiovascular events (MACE), cardiovascular death, and all-cause mortality in patients with Type 2 Diabetes and high cardiovascular risk.Strong
- Liraglutide 3.0 mg/day significantly reduces body weight in adults with obesity or overweight (BMI ≥30 or ≥27 with comorbidities) compared to placebo, with effects sustained over 56 weeks.Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →